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Summary
 
Mechanisms responsible for neuroattenuation of herpes simplex virus (HSV) have been defined
previously by studies of mutant viruses in cultured cells. The hypothesis that null mutations in
host genes can override the attenuated phenotype of null mutations in certain viral genes was
tested. Mutants such as those in infected cell protein (ICP) 0, thymidine kinase, ribonucleotide
reductase, virion host shutoff, and ICP34.5 are reduced in their capacity to replicate in nondi-
viding cells in culture and in vivo. The replication of these viruses was examined in eyes and
trigeminal ganglia for 1–7 d after corneal inoculation in mice with null mutations (
 
2/2
 
) in in-
terferon receptors (IFNR) for type I IFNs (IFN-
 
a/b
 
R), type II IFN (IFN-
 
g
 
R), and both type
 
I and type II IFNs (IFN-
 
a/b/g
 
R)
 
.
 
 Viral titers in eyes and ganglia of IFN-
 
g
 
R
 
2/2
 
 
 
mice were not
significantly different from congenic controls. However, in IFN-
 
a/b
 
R
 
2/2
 
 or IFN-
 
a/b/g
 
R
 
2/2
 
mice, growth of all mutants, including those with significantly impaired growth in cell culture,
was enhanced by up to 1,000-fold in eyes and trigeminal ganglia. Blepharitis and clinical signs
of infection were evident in IFN-
 
a/b
 
R
 
2/2
 
 and
 
 
 
IFN-
 
a/b/g
 
R
 
2/2
 
 but not control mice for all vi-
ruses. Also, IFNs were shown to significantly reduce productive infection of, and spread from
intact, but not scarified, corneas. Particularly striking was restoration of near-normal trigeminal
ganglion replication and neurovirulence of an ICP34.5 mutant in IFN-
 
a/b
 
R
 
2/2
 
 mice. These
data show that IFNs play a major role in limiting mutant and wild-type HSV replication in the
cornea and in the nervous system. In addition, the
 
 
 
in vivo target of ICP34.5 may be host IFN
responses. These experiments demonstrate an unsuspected role for host factors in defining the
phenotypes of some HSV mutants in vivo. The phenotypes of mutant viruses therefore cannot
be interpreted based solely upon studies in cell culture but must be considered carefully in the
context of host factors that may define the in vivo phenotype.
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I
 
n humans and experimental animals the pathogenesis of
herpes simplex virus (HSV)-1
 
1
 
 occurs in a series of dis-
crete stages (1). Acute viral replication at a peripheral site
such as the cornea is followed by viral entry into neuronal
termini. Corneal infection is followed by intra-axonal
transport, which moves the virus to the trigeminal ganglia,
where further replication may occur before clearance of in-
fectious virus and the establishment of latency. Failure to
clear the virus may result in central nervous system infec-
tion, encephalitis, and death. Latency may periodically
break down in response to certain stimuli, leading to viral
reactivation and shedding. The host factors that regulate
the discreet stages of pathogenesis are incompletely defined.
In this paper, the role of host IFNs in determining the
phenotypes of herpesvirus mutants in vivo is examined.
The ability to create recombinant viruses coupled with the
availability of a variety of laboratory animal models of HSV
infection have elucidated the roles of viral genes in specific
stages in pathogenesis (2–6). Studies with mutant viruses
have shown that many HSV genes are dispensable for viral
replication in dividing cells (7). However, such mutants of-
ten fail to replicate efficiently in nondividing cultured cells.
In animal models, such genes often play key roles, particu-
larly in promoting acute replication either at the primary
site of infection or in the nervous system (2, 6, 8–10). To
date, studies of HSV mutants have generally assumed, first,
that in vivo
 
 
 
phenotypes observed are determined solely by
 
1
 
Abbreviations used in this paper:
 
 ICP, infected cell protein; HSV, herpes
simplex virus; PKR, double-stranded RNA-dependent protein kinase R;
 
rr
 
, ribonucleotide reductase; 
 
tk
 
, thymidine kinase; 
 
vhs
 
, virion host shutoff. 
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specific virus-cell interactions, and second, that the func-
tion of the gene (for example, promotion of efficient repli-
cation in nondividing cells) demonstrated in cell culture
must correlate with and account for phenotypic differences
observed in vivo. Only a few studies have examined a role
for the host immune system in influencing the in vivo
 
 
 
phe-
notypes of HSV strains and mutants. For example, infected
cell protein (ICP)47 has been shown to influence neurovir-
ulence by blocking CD8
 
1
 
 T cell responses, and certain
large genomic fragments of HSV-1 and HSV-2 strains have
been shown to confer resistance to IFNs, although specific
genes have not been identified (5, 11, 12). This line of in-
vestigation is especially relevant to those viruses whose
growth in culture is significantly reduced due to mutation
of a transactivation function such as ICP0 (13, 14), or a
DNA replication function such as ribonucleotide reductase
(
 
rr
 
) or thymidine kinase (
 
tk
 
), without which the virus can-
not thrive in nondividing cells (15, 16). Restoration of
normal virulence to attenuated viral mutants by deletion
of specific host factors defines these factors as likely targets
of the viral gene in question. With these considerations in
mind, the hypothesis was tested that the host IFN response
may be an additional, or even strongly determining, influ-
ence on the phenotype of herpesvirus mutants.
For these studies, HSV mutants were selected to repre-
sent genes from each kinetic class and a variety of functions
(Table I). All mutants examined have been intensively
characterized in vitro and in vivo and their phenotypes
proven to be due to mutation of the targeted gene either
through marker-rescue or examination of independently
isolated mutants. These mutants are capable of replication
in cell under some conditions. However, in nondividing
cells some of these mutants are significantly impaired for
replication (Table I). All of them have been shown to play
important roles in pathogenesis and replication in vivo.
Infected cell protein (ICP) 0, an immediate-early gene,
nonspecifically stimulates the expression of all classes of
HSV and cellular genes at the transcriptional level (17–21).
ICP0 is packaged in the virion and after infection colocal-
izes with and redistributes nuclear domain 10 antigens, and
also attenuates DNA-dependent protein kinase activity (22,
23). ICP0 null mutant viruses exhibit significantly reduced
replication in culture, especially at low multiplicities of in-
fection and at certain points in the cell cycle (24). The crit-
ical role of ICP0 in regulating viral and host gene expres-
sion is thought to be sufficient to explain the fact that ICP0
mutant viruses are severely compromised in animal models,
exhibiting impaired replication, establishment of latency,
and reactivation (2, 25). A role for host factors in determin-
ing the in vivo phenotype of ICP0 mutants has not been
demonstrated.
The early genes 
 
tk
 
 and 
 
rr
 
 are two of several nucleotide
metabolism enzymes that allow HSV to replicate autono-
mously of the cell-cycle status of the host cell. Viral 
 
tk
 
phosphorylates deoxypyrimidine nucleosides and 
 
rr
 
 cata-
lyzes the reduction of ribonucleoside triphosphates (26,
27). Both genes are dispensable in dividing cells, but are es-
sential for viral replication in nonmitotic cells, where it is
thought that cellular homologues are not present in suffi-
cient quantity to compensate for 
 
rr
 
 or 
 
tk
 
 null mutations (10,
15). In mice, mutants in 
 
rr
 
 or 
 
tk
 
 are significantly impaired
for replication in the cornea, although the extent of impair-
ment for 
 
rr
 
 mutants depends on the nature of the mutation
(4, 6, 28). However, in all cases mutant viruses are cleared
more rapidly than are wild-type virus. Reduced replication
in eyes has been proposed to be due to an inability of 
 
rr
 
mutants to replicate efficiently at 38
 
8
 
C in mouse cells, cou-
pled with the nonmitotic status of much of the corneal ep-
ithelium (28). In the adult nervous system, replication of 
 
rr
 
and 
 
tk 
 
mutants is undetectable and these mutants can estab-
lish latency but are unable to reactivate. The lack of repli-
cation in the nervous system is clearly consistent with the
limited nucleotide metabolism in neurons, and a role for
host factors in determining the in vivo phenotypes of 
 
rr
 
 or
 
tk
 
 mutants has not been demonstrated.
Mutants in virion host shutoff (
 
vhs
 
) and ICP34.5 were of
particular interest in these studies, primarily because the
highly significant degree of attenuation of such mutants in
vivo suggests a strong role for host factors in determining
the mutant phenotype given their near wild-type replica-
 
Table I.
 
Summary of HSV-1 Mutants Used in this Study
 
Virus 
(parent strain) Mutated gene Kinetic class
Abbreviation 
in this study
Growth defect 
in culture
Growth defect
in vivo Reference
KOS Wild-type N/A KOS None None 64
 
dlx
 
3.1 (KOS) ICP0 Immediate-early
 
D
 
0 All cells Cornea/neurons 13
 
hr
 
R3 (KOS)
 
rr
 
Early
 
D
 
RR Nondividing cells Cornea/neurons 15, 65
 
dl
 
8.36tk (KOS)
 
tk
 
Early
 
D
 
TK Nondividing cells Neurons 4, 47
UL41NHB (KOS)
 
vhs
 
Late
 
D
 
vhs None All cells 29
17TermA (17) ICP34.5 Late
 
D
 
34.5 Nondividing cells Neurons 9
17TermA
 
R
 
 (17) Marker rescue 
of 17TermA N/A
 
D
 
34.5
 
R
 
None None 9
N/A, not applicable. 
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tion in culture (9, 29). 
 
vhs
 
 is a tegument protein that in-
duces the destabilization of host mRNA, leading to rapid
cessation of host protein synthesis after infection (30). 
 
vhs
 
also degrades viral mRNAs and serves to facilitate the tran-
sition of viral gene expression from one kinetic class to the
next. The effect of 
 
vhs
 
 deletion on viral replication in cell
culture is modest, but is very significant in mice, in the cor-
nea, trigeminal ganglion, and the brain (29). The poor rep-
lication at the periphery probably explains the requirement
for 
 
vhs
 
 for the efficient establishment of latency (31).
ICP34.5 shows homology to the DNA damage protein
GADD34 and acts by precluding the shutoff of protein
synthesis associated with apoptosis by regulation of the
IFN-inducible double-stranded RNA-dependent protein
kinase R (PKR) pathway (32, 33). The effect of deletion of
ICP34.5 upon replication in permissive cells is minimal,
but ICP34.5 mutants are impaired for replication in the
cornea (9, 34, 35). More importantly, these mutants are
profoundly neuroattenuated in trigeminal ganglia after cor-
neal infection, and in the brain after intracranial injection
(9, 35, 36). It is possible that the replication of ICP34.5
mutants may be cell cycle dependent, explaining why such
mutants fail to replicate efficiently in postmitotic or qui-
escent cells. Specific host factors that influence the pheno-
types of 
 
vhs
 
 or ICP34.5 mutants in vivo have not been
identified fully.
The immune response to acute HSV infection involves
both innate and acquired immunity. The fact that all mu-
tants examined in this study show striking attenuation
within 1 to 2 d after infection suggested a pivotal role for
mediators of innate immunity. Key mediators of innate re-
sistance to viral infection include the IFNs, although the
precise mechanisms by which they exert their effect upon
HSV infection is not fully understood. IFN-
 
a
 
 has been
shown to inhibit the onset of immediate-early HSV gene
expression, and in mice IFN-
 
a
 
 is a potent inhibitor of rep-
lication in the cornea (37–40). In addition, IFN-
 
a/b
 
 serves
to activate host defenses such as NK cells, which have
themselves been shown to be important in controlling
HSV infection and pathology (41). IFN-
 
a/b
 
 has also been
suggested to be important for limiting progress of infection
from peripheral tissues to the nervous system (42). IFN-
 
g
 
has been perhaps the most extensively studied of the IFNs
in HSV infection. IFN-
 
g
 
 has been shown to vary widely in
its efficacy in reducing HSV growth depending on its target
cell, and in culture, HSV replication appears less sensitive
to inhibition by IFN-
 
g
 
 than to IFN-
 
a/b
 
 (43). However, it
appears that IFN-
 
g
 
 may play an important role in the clear-
ance of HSV from the cornea and in resistance to encepha-
litis, possibly by inhibiting apoptosis of neurons (44, 45).
In this study, mice that are genetically altered in their
abilities to respond to IFNs by virtue of null mutations in
IFNRs were corneally infected with mutant viruses whose
ability to replicate in normal mice has been shown to be
significantly reduced either in corneas or trigeminal gan-
glia, or both. The data indicate that the phenotypes of a va-
riety of viruses is significantly impacted by the ability of the
infected mice to respond to IFNs. The phenotype of HSV
mutants therefore must always be interpreted with careful
regard to the host’s immune response.
 
Materials and Methods
 
Viruses and Cells.
 
African green monkey kidney (Vero) cells
were propagated and growth and assay of all virus strains was
done as previously described (46). The KOS strain of HSV-1 was
the background for mutant viruses 
 
dlx
 
3.1 (ICP0 deletion termed
here 
 
D
 
0, provided by Dr. Priscilla Schaffer, University of Penn-
sylvania, Philadelphia, PA [13]), 
 
hr
 
R3 (ribonucleotide reductase
deletion termed here 
 
D
 
RR, provided by Dr. Sandra Weller,
University of Connecticut, Farmington, CT [15]), UL41NHB
(
 
vhs 
 
nonsense mutation termed here 
 
D
 
vhs [29]), and 
 
dl
 
8.36
 
tk
 
 (
 
tk
 
deletion, termed here 
 
D
 
tk [47]). The ICP34.5 mutant, 17TermA
(termed here 
 
D
 
34.5) and its marker-rescued virus, 17TermA
 
R
 
(termed here 
 
D
 
34.5
 
R
 
), were made in the background of strain 17
and were provided by Dr. Richard Thompson, University of
Cincinnati, Cincinnati, OH (9). A summary of information and
abbreviations on all seven viruses used in this study is provided in
Table I.
 
Mouse Strains.
 
All animal handling and procedures were in
compliance with Federal and University policies. Mice were
housed and bred in the Washington University School of Medi-
cine biosafety level 2 animal facility, where sentinel mice were
screened every 3–6 mo for mouse pathogens and determined to
be negative. All mice used in this study were in a pure 129 Ev/Sv
(referred to as 129) background and 129 mice were used as im-
munocompetent controls. Mice deleted for IFNRs used were
IFN-
 
a/b
 
R
 
2/2
 
, IFN-
 
g
 
R
 
2/2
 
, and IFN-
 
a/b/g
 
R
 
2/2
 
, and were all
originally obtained from Michel Aguet (Swiss Institute for Exper-
imental Cancer Research, Lausanne, Switzerland; 48).
 
Animal Procedures.
 
6–8-wk-old mice were anesthetized with
xylazine and ketamine, corneas were scarified with 10 interlock-
ing strokes with a 27-gauge needle, and 5 ml of medium contain-
ing 2 3 104 or 2 3 106 PFU of virus was added per eye. Lids
were massaged together briefly to promote adsorption of virus.
Eye swab and trigeminal ganglion assays of acute infection were
performed as previously described (29). In brief, for eye swabs,
eyes were proptosed and moistened cotton swabs used to sample
the surface of the eye, going three times in a circular fashion
around the eye and twice across the eye making an “x”, before
placing the swab in 1 ml of tissue culture medium. Sampled
trigeminal ganglia were homogenized in 1 ml of tissue culture
medium using 1-mm beads in a Mini-Beadbeater-8 (Biospec
Products). All samples were titered using standard plaque assay on
Vero cells. All data presented are logarithmic means 6 SEM and
the limit of detection was 10 PFU. Clinical signs of infection
(eyelid swelling and loss of facial hair) were measured on a semi-
quantitative scale of 0–4 as previously described (49). All mouse
procedures conformed to protocols approved by the Washington
University Animal Studies Committee.
Results
Infection of Immunocompetent 129 Mice. The replication of
KOS and other mutants used in this study has not been
studied previously in strain 129 mice. Therefore, it was im-
portant to determine that the patterns of growth seen in
other wild-type mouse strains were reproduced in strain
129. The replication in eyes of Dvhs, DRR, and D0 mutant
viruses was reduced relative to KOS in 129 wild-type ani-666 Interferons and Herpes Simplex Pathogenesis
mals (Fig. 1 A). The replication of the DRR mutant was
reduced by z10–1,000-fold and was cleared more rapidly
than KOS. The growth of the D0 and Dvhs mutants was
more significantly impaired, up to 10,000-fold relative to
KOS. This is especially notable for the Dvhs mutant, whose
replication in tissue culture is essentially identical to that
of KOS. In trigeminal ganglia of 129 mice, the replication
of all viral mutants was undetectable on day 3 after infec-
tion, at which time the titer of KOS was .104 PFU per ml
(Fig. 1 B), day 3 being the peak of viral replication in the
trigeminal ganglion. Taken together, these data show that
these mutants exhibit impaired replication in 129 mice rel-
ative to wild-type virus in both corneas and trigeminal gan-
glia, consistent with previously published data (Table I and
references 2, 6, 29).
Infection of IFN-gR2/2 Mice. Previous work from other
laboratories showed that the deletion of IFN-gR had little
impact upon early acute wild-type HSV infection in mice
(50), while others have argued for an important role (44,
45). To examine this further, IFN-gR2/2 mice were in-
fected with 2 3 106 PFU with either KOS or Dvhs. Con-
sistent with these previous studies, the early acute replica-
tion patterns of KOS and Dvhs were unaltered whether
examined in 129 or IFN-gR2/2 mice (Fig. 1, C and D).
Figure 1. (A) Replication of wild-type
KOS and mutants in vhs (Dvhs), rr (DRR),
and ICP0 (D0) in eyes of control 129 mice
from day 1 to day 4 after infection. Values
are logarithmic means for at least eight sam-
ples for each virus. (B) Replication of KOS,
and  D0,  D34.5vhs, and DRR viruses in
trigeminal ganglia of control 129 strain mice
3 d after infection. Values are logarithmic
means for at least eight samples for each vi-
rus. (C) Replication of wild-type KOS and
Dvhs  mutant viruses in eyes of 129 mice
from days 1 to 3 after infection. Values are
logarithmic means for four samples for each
virus. (D) Replication of KOS and Dvhs vi-
ruses in eyes of IFN-gR2/2 mice from days
1 to 3 after infection performed in parallel
with the experiment shown in C. Values are
logarithmic means of four samples for each
virus.
Figure 2. (A) Replication of KOS and
mutants in ICP0 (D0), rr (DRR), and vhs
(Dvhs), and in eyes of IFN-a/bR2/2 mice
from day 1 to day 4 after infection. Values
are logarithmic means for at least eight sam-
ples for each virus. (B) Replication of KOS,
D0, DRR, and Dvhs in the eyes of IFN-
a/b/gR2/2 mice from days 1 to 3 after in-
fection. Values are logarithmic means for at
least four samples for each virus. (C) Repli-
cation of ICP0 mutant virus D0 in trigemi-
nal ganglia of control 129 strain and IFN-
a/b/gR2/2 mice from days 3, 5, and 7 after
infection. Values are logarithmic means for
eight samples for each virus. (D) Replica-
tion of vhs mutant virus Dvhs in trigeminal
ganglia of control 129 strain and IFN-a/b/
gR2/2 mice from days 3, 5, and 7 after in-
fection. Values are logarithmic means for
eight samples.667 Leib et al.
Infection of IFN-a/bR2/2 and IFN-a/b/gR2/2 Mice.
To determine the role of IFN-a/b in the reduced growth
phenotypes of the mutant viruses, IFN-a/bR2/2 and
IFN-a/b/gR2/2 mice were infected in parallel with 129
mice, with wild-type or mutant viruses (Fig. 2, A and B).
In the eyes of the IFNR2/2 mice there was an increase in
replication of z10-fold on days 1–4 after infection for
KOS, relative to growth in 129 mice. For D0 and DRR in
IFN-a/bR2/2 and IFN-a/b/gR2/2 mice, there was a very
significant enhancement of viral replication, with 104–105
PFU per ml in eye swab samples. At comparable times in
129 mice, titers for these mutants were 100 PFU per ml or
undetectable. These enhanced titers were such that they
were within 10-fold of the titers seen for KOS. Titers for
Dvhs were enhanced by 10–100-fold in IFN-a/bR2/2 and
IFN-a/b/gR2/2 mice. Although this enhancement was
significant (P , 0.001 by Student’s t test), it was reproduc-
ibly less than was seen for D0 and DRR. Overall, the pat-
terns of viral replication were very similar in IFN-a/bR2/2
and IFN-a/b/gR2/2 mice. Given that the IFN-a/b/gR2/2
mice are derived from crossing IFN-a/bR2/2 with IFN-
gR2/2 mice, these data are consistent with observations of
previous work (50) as well as this study, indicating that
IFN-g plays only a minor additional role to IFN-a/b in
controlling early acute infection.
Initial experiments in IFN-a/bR2/2 and IFN-a/b/gR2/2
mice showed that the replication of D0 and Dvhs was un-
detectable in trigeminal ganglia on day 3 after infection,
normally the peak of viral replication in the ganglion (2).
However, longer time course experiments in IFN-a/bR2/2
(data not shown) and IFN-a/b/gR2/2 (Fig. 2, C and D)
mice revealed that D0 and Dvhs were capable of replication
to readily detectable levels in trigeminal ganglia of IFN-a/b/
gR2/2 mice when sampled from day 3 onwards, ranging
from 101 to 104 PFU per ml of ganglion homogenate. At
these times, both mutant viruses were undetectable in the
trigeminal ganglia of 129 mice.
Taken together, these data show that all viruses tested,
even those with severe growth restrictions in vivo due to
disparate mutations, can replicate with significantly in-
creased efficiency in IFN-a/bR2/2 and IFN-a/b/gR2/2
mice in both eyes and trigeminal ganglia. Furthermore,
patterns of replication seen in IFN-a/bR2/2 mice were
comparable to those seen in IFN-a/b/gR2/2 mice.
Characterization of tk and ICP34.5 Mutants in IFNR2/2
Mice. Viruses containing mutations in tk and ICP34.5
have been extensively characterized in vivo in terms of rep-
lication, neurovirulence, and establishment and reactivation
of latency. As described in the introduction, explanations
for their neuroattenuation have been formulated from a
large body of data. Thus, these mutants were examined
more closely in this study to assess the impact of IFNs on
their phenotypes.
The replication of Dtk was significantly enhanced (10–
100-fold) in the corneas of IFN-a/b/gR2/2 compared with
129 mice (Fig. 3 A). In 129 mice, Dtk was cleared by day 5,
at which time there was .103 PFU per ml persisting in the
IFN-a/b/gR2/2 mice. In addition, blepharitis and periocu-
lar lesions became evident in the IFN-a/b/gR2/2 mice by
day 7, whereas the 129 mice looked essentially uninfected.
Moreover, Dtk replication was readily detected in trigemi-
nal ganglia of IFN-a/b/gR2/2 mice on days 3, 5, and 9,
whereas, consistent with previous observations in wild-type
mice, no virus was detectable in the 129 mice (Fig. 3 B).
The ICP34.5 mutant, D34.5, was the only mutant tested
in this study whose corneal replication was only modestly
higher in IFN-a/bR2/2 compared with 129 mice, with a
,10-fold increase over the first 3 d of infection (Fig. 4, A
and B). However, the mutant was cleared more rapidly
from 129 than IFN-a/bR2/2 mice. Similar to wild-type
KOS, the marker-rescued virus D34.5R showed .10-fold
increased replication in IFN-a/bR2/2 eyes compared with
129 mice. Replication of D34.5 was not detectable in ganglia
of 129 mice at any time (Fig. 4 C). In contrast, replication of
D34.5 in the trigeminal ganglia of IFN-a/bR2/2 mice was
robust with a titer of 104 PFU per ml on day 3 and 3 3 104
on day 5, these titers being at most 10-fold less than its
marker-rescued virus D34.5R (Fig. 4 D). Moreover, all
IFN-a/bR2/2 mice infected with D34.5 that were not killed
for trigeminal ganglion data died on or before day 9 after in-
fection with symptoms consistent with viral encephalitis.
Data comparable to those seen for D34.5 and D34.5R repli-
cation in IFN-a/bR2/2 mice were also observed in corneas
and ganglia of IFN-a/b/gR2/2 mice (data not shown).
Infection of Scarified and Nonscarified IFN-a/b/gR2/2 Mice.
Corneal scarification is a prerequisite for efficient uptake of
HSV and other materials in normal mice such as horserad-
ish peroxidase from the cornea into the trigeminal ganglion
Figure 3. (A) Replication of a tk mutant
virus, Dtk in corneas of control 129 and
IFN-a/b/gR2/2 mice from days 1–5 after
infection. Values are logarithmic means for
eight samples. (B) Replication of Dtk in
trigeminal ganglia of control 129 and IFN-
a/b/gR2/2 mice from days 2, 3, 5, and 9 af-
ter infection. Values are logarithmic means
for eight samples.668 Interferons and Herpes Simplex Pathogenesis
(51). In the absence of scarification, replication of KOS
both at the cornea and in ganglia is extremely limited (Stre-
low, L.I., and D.A. Leib, unpublished data, and Fig. 5).
Therefore, infection of neurons is thought to be the result
of direct uptake into axonal termini coupled with local am-
plification and subsequent retrograde axonal transport of
virus. Since IFNs played a key role in determining the cor-
neal phenotype of even very attenuated viruses, it was of
interest to assess whether corneal scarification is actually
needed for establishment of HSV corneal infection in the
absence of IFN responsiveness. Control 129 and IFN-a/b/
gR2/2 mice were either scarified or not and infected with
2 3 106 PFU of KOS. In 129 mice, there was robust repli-
cation of KOS in scarified corneas, with titers .2 3 104
PFU per ml 4 d after infection (Fig. 5 A). In contrast, repli-
cation in the nonscarified group was undetectable with one
virus-positive sample (out of eight) on day 2 after infection.
However, in IFN-a/b/gR2/2 mice, replication was readily
detected in both scarified and nonscarified mice, although
there was a delay in onset of replication in the nonscarified
group. The level of replication in the scarified IFN-a/b/
gR2/2 mice was significantly higher than in the nonscari-
fied mice at all time points tested. A similar pattern of repli-
cation emerged in the trigeminal ganglia (Fig. 5 B). In 129
mice, replication was virtually undetectable in nonscarified
mice, but robust in scarified mice. In IFN-a/b/gR2/2 mice,
replication was readily detectable for both scarified and
nonscarified groups, but there was a delay in onset of repli-
cation in the nonscarified group. By day 4, titers of virus in
the nonscarified IFN-a/b/gR2/2 mice were comparable to
those of scarified 129 mice. These data show that the IFNs
play a key role in determining the outcome of viral infec-
tion of the intact cornea.
Discussion
The results presented in this study indicate that the acute
replication patterns in eyes and trigeminal ganglia of both
mutant and wild-type viruses tested are significantly im-
pacted by IFNs. In particular, this study underscores the
critical role played by IFN-a/b in the control of early acute
replication of HSV, and the relatively minor role of IFN-g.
Figure 4. Replication of an ICP34.5 mu-
tant virus, D34.5, and marker-rescued virus
D34.5R, in corneas of (A) control 129 strain
and (B) IFN-a/bR2/2 mice from days 1 to
5 after infection. Replication of D34.5 and
D34.5R in trigeminal ganglia of (C) control
129 and (D) IFN-a/bR2/2 mice on days 3,
5, and 7 after infection are also shown. Val-
ues represent logarithmic means for eight
samples.
Figure 5. Replication of KOS
in (A) corneas and (B) trigeminal
ganglia of control 129 and IFN-
a/b/gR2/2 mice from days 1 to
4 after infection. Corneas were
either scarified or left undamaged
before infection with 2 3 106
PFU of KOS. Values represent
logarithmic means for four sam-
ples in a representative experi-
ment.669 Leib et al.
These data are consistent with those of Su et al. (52), who
showed that neutralizing antibody-mediated depletion of
IFN-a/b led to a .1,000-fold increase in ocular viral titers
and a corresponding increase in corneal opacity after infec-
tion with wild-type HSV-1. Correspondingly, the data of
Cantin et al. (50) showed a less than twofold increase in vi-
ral titers in trigeminal ganglia of IFN-gR2/2 mice com-
pared with control isogenic mice. These protective effects
of IFN-a/b in mice are likely to be due to induction of an
antiviral state in target cells coupled with activation of
other nonspecific host defenses such as NK cells and proba-
bly represents the first line of defense against HSV infec-
tion. With respect to NK cells, one study showed that re-
sistance to acute wild-type HSV-1 infection correlated to
early IFN production but not NK cell activity, suggesting
that NK cell activation is not the primary mechanism of
IFN-mediated resistance (53). A specific role for IFNs is
further supported by the observation that, in contrast to data
presented here for IFN-a/bR2/2 mice, tk and ICP34.5 mu-
tants are incapable of significant replication in the nervous
system of SCID mice, which lack adaptive immunity but
express and respond to IFNs (54–56).
The behavior of the tk and ICP34.5 mutants in IFN-
a/bR2/2 and IFN-a/b/gR2/2 mice is of particular interest
and worthy of further discussion. Both of these genes have
been extensively studied and shown by several independent
laboratories to be critical determinants of viral replication
in the nervous system and to be essential for efficient pe-
ripheral neuroinvasion. tk mutants in the mouse eye model
typically show robust (albeit reduced relative to wild-type
virus) replication in the cornea, with little or no replication
observed in the trigeminal ganglion (4). However, tk
mutants do establish latency, as judged by the presence of
viral DNA in the ganglion, although with 10-fold reduced
efficiency (57). Reactivation, however, is minimal or ab-
sent. The lack of tk mutant virus replication and reactiva-
tion in neurons is consistent with the absence of comple-
mentary host tk activity in nondividing cells. How, then, is
a tk mutant able to replicate in the nervous system of
IFNR2/2 mice as shown in this study? One clue comes
from the observations that tk mutants can be made to reac-
tivate by addition of thymidine to the culture medium of
latently infected ganglia and that IFN-a can significantly
reduce steady state levels of thymidine and thymidine me-
tabolites in HSV-infected cells (58, 59). Therefore, it is
possible that the lack of IFN-a/b receptors in the knockout
mice leads to higher intracellular levels of thymidine in the
nervous system, thereby allowing a tk-deleted virus to rep-
licate to detectable and significant levels. An alternate hy-
pothesis is that the increased viral replication and persis-
tence in the cornea leads to a higher viral load in the
ganglion with a concomitant rise in viral trans-acting fac-
tors such as VP16 and ICP0, thereby promoting a lytic in-
fection. This hypothesis seems unlikely since increasing the
infectious dose of mutant virus does not promote replica-
tion in the ganglion if the virus is inherently crippled for
replication at that site (Strelow, L.I., and D.A. Leib, un-
published data). In addition, such increased levels of trans-
acting factors would probably not be able to overcome a
block in thymidine metabolism and DNA replication.
ICP34.5 mutants exhibit significantly reduced replica-
tion in eyes of wild-type mice and minimal replication in
the nervous system after peripheral infection. This lack of
replication and neurovirulence is believed to be due to the
ability of ICP34.5 to preclude the shutoff of protein syn-
thesis by IFN-inducible PKR (32, 33). IFNs induce the
synthesis of PKR in an inactive form, which subsequently
becomes activated by binding of viral doubled-stranded
RNA and homodimerization. Once activated, PKR causes
the phosphorylation of the basal translation initiation factor
eIF2a such that translation and protein synthesis are ar-
rested. ICP34.5 interferes with this host protective pathway
by binding to and redirecting the activity of protein phos-
phatase 1 to dephosphorylate the basal translation factor
eIF-2a, thereby prolonging protein synthesis and viral rep-
lication. Cells infected with ICP34.52 viruses therefore ex-
hibit premature shutoff of protein synthesis. Thus, one hy-
pothesis to explain the data in this study is that the
significantly increased neurovirulence of the ICP34.5 mu-
tant in IFN-a/bR2/2 and IFN-a/b/gR2/2 mice is due to
reduced intracellular levels of PKR that result from an in-
ability to respond to IFNs. A lack of PKR would result in
low efficiency phosphorylation of eIF-2a and an inability
of the host to shut off protein synthesis, obviating the need
for ICP34.5. This could explain why ICP34.5 mutants ex-
hibit almost wild-type virulence and replication in IFNR-
a/b2/2 mice. This near wild-type replication and lethality
of this severely neuroattenuated virus should be addition-
ally considered in the light of ongoing phase 1 clinical trials
using intracranial injection of ICP34.5 mutants for treat-
ment of human glioma (60). The use of viruses singly de-
leted in the ICP34.5 locus may present a potentially lethal
challenge to those individuals with any deficiencies in IFN
responses. The use of viruses with double deletions, such as
ICP34.5, in addition to ribonucleotide reductase may
therefore be preferable (61).
The phenotypes of the ICP0 and vhs mutants in IFNR2/2
mice are also worthy of discussion. With respect to ICP0, it
has been shown that the growth of ICP0 mutants is com-
pensated by a host function which is expressed 8 h after re-
lease from G0/G1 cell-cycle arrest (24). In wild-type mice,
the expression and response to IFNs after virus infection
may lead to a nonproliferative state in infected cells. In
IFNR2/2 mice, IFNs cannot induce such a nonprolifera-
tive state, allowing more cells to remain freely cycling.
Therefore, it is possible that greater replication of ICP0
mutants observed in IFNR2/2 mice is due, at least in part,
to an enhanced level of expression of the complementary
host factor due to a higher level of proliferation in infected
cells.
The phenotype of the vhs mutant is enigmatic in the
sense that it is the least compromised in terms of its replica-
tion in cell culture and yet the most compromised in mice
(29). Moreover, it is the virus whose replication in the cor-
nea is least enhanced by lack of IFN responsiveness. How-
ever, the observation of significant replication of Dvhs in670 Interferons and Herpes Simplex Pathogenesis
the trigeminal ganglion is consistent with the idea that the
replication of this mutant is not compromised in the ner-
vous system to the same extent that it is in the cornea.
When Dvhs can gain access to the nervous system either by
corneal infection of IFN-a/b/gR2/2 mice or intracerebral
infection of wild-type mice (29), the virus can replicate to
significant levels. The fact that the mutants tested in
IFNR2/2 mice in this study do not behave in the same way
strongly suggests that there is some degree of specificity to
the phenotypes observed and not just a global enhancement
of all viral replication to the same level. There is, therefore,
an IFN-independent impairment of vhs mutant virus repli-
cation in vivo. Whether this is related to the observed al-
terations in MHC class I expression previously reported is
an important issue for further experimentation (62).
The intact cornea is an effective barrier to HSV infec-
tion, and thus many experimental eye models employ cor-
neal scarification as a means to promote peripheral infec-
tion and nervous system invasion (34, 46, 63). However,
the extent to which virus can penetrate the cornea without
scarification is virus strain dependent. Strain KOS, used in
this study, has been shown in mice and rabbits to be virtu-
ally incapable of corneal and nervous system invasion with-
out prior scarification, whereas HSV-1 strain McKrae can
penetrate without scarification (34). The mechanism by
which scarification promotes viral invasion is not known,
but a common assumption is that the mechanical damage
to the corneal epithelium permits direct access to the nerve
termini, allowing a conduit into the peripheral nervous sys-
tem. The data in this study suggest that major determinants
of corneal resistance to viral invasion are the IFNs, since
KOS was capable of robust replication in corneas and gan-
glia of nonscarified IFNR2/2 mice. This is consistent with
the idea that different HSV strains may be differentially sus-
ceptible to the effects of IFNs (11, 12).
In conclusion, this study has shown the critical role
played by IFN, especially IFN-a/b, in controlling early
acute HSV infection, and has also shown that in the ab-
sence of IFN responsiveness mice are highly susceptible to
infection even by very attenuated viruses. These studies
show that the attenuation of viral mutants must be carefully
considered within the context of the immune response, es-
pecially early-onset innate immunity. Furthermore, any at-
tenuation of growth of HSV mutants in culture should be
examined with respect to IFNs. The use of these and other
genetically altered mice will now allow study of the inter-
actions of viral genes and cytokines during the establish-
ment, maintenance, and reactivation of viral latency.
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